Core Points - Genmab A/S announced the pricing of $1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion of 7.250% senior unsecured notes due 2033, with an issue price of 100.000% [1] - The company has completed the syndication of a new $2.0 billion senior secured term loan "B" facility, in addition to existing credit facilities [2] - The net proceeds from the notes offering will be used to fund the acquisition of Merus N.V. and related expenses [3] Financing Details - The total financing includes $1.5 billion in secured notes and $1.0 billion in unsecured notes, alongside a $2.0 billion senior secured term loan "B" facility [1][2] - The secured notes will be backed by segregated accounts prior to the acquisition closing, and will later be secured by a first priority interest in certain assets of Genmab and its subsidiaries [4] - The indentures governing the notes will include covenants that restrict Genmab and its subsidiaries from incurring additional debt and other financial activities [5] Regulatory Information - The notes have not been registered under the Securities Act and are available only to qualified institutional buyers or non-U.S. persons [6] - The offering does not constitute an offer to sell or a solicitation of an offer to purchase any securities [7]